Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

SAN DIEGO – January 2, 2018 – Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced that Scott Struthers, Ph.D., founder and chief executive officer, will present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018 at 11:30 a.m. PT. The conference is being held at the Westin St. Francis Hotel in San Francisco.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a clinical-stage biotechnology company focusing on treatments for rare endocrine disorders and endocrine-related cancers. The company is currently conducting a Phase 1 trial with its oral somatostatin agonist, CRN00808, for the treatment of acromegaly, an orphan disease affecting more than 24,000 people in the United States. The company is also developing other oral somatostatin agonists for neuroendocrine tumors, hyperinsulinism, and chronic pain, as well as an oral small molecule for Cushing’s disease. Crinetics was founded by a team of scientists with a proven track record of endocrine drug discovery and development. The company is backed by top life sciences investors including 5AM Ventures, Versant Ventures and Vivo Capital, and is headquartered in San Diego.